We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Spinal Cement Procedures May Be Ineffective

By HospiMedica staff writers
Posted on 09 Jun 2006
Spinal cement procedures have not been shown to improve a person's back pain or quality of life, according to a new analysis of studies. More...


Researchers at ECRI (Plymouth Meeting, PA, USA) reviewed 16 studies of percutaneous kyphoplasty, a procedure that fills in fractured vertebrae with injected cement, mostly in osteoporosis patients. The procedure was performed in both the lumbar (lower back) and thoracic (middle back) vertebrae. The analysis found that kyphoplasty did seem to expand areas of collapsed backbone and restore some vertebral height in patients with osteoporosis, but the studies did not offer enough information to precisely measure the magnitude of these improvements.

None of the patients in the 16 studies died as a result of kyphoplasty. Leaking bone cement was the most common side effect of the treatment, occurring in up to 34% of vertebrae. The report was released as an ECRI Health Technology Information Service (HTAIS) in March 2006.

"To the best of our knowledge, we don't believe there is any evidence out there that would suggest kyphoplasty is more effective when used on lumbar or thoracic vertebrae,” said Dr. Stephen Tregear, director of special projects for ECRI. "The lack of studies directly comparing kyphoplasty to more simple treatments such as bed rest prevented us from being able to determine whether percutaneous kyphoplasty improves patients' pain, functional ability, or quality of life.

ECRI (formerly the Emergency Care Research Institute) is a nonprofit health services research agency and a collaborating center of the World Heath Organization (WHO, Geneva, Switzerland). ECRI has locations worldwide and is widely recognized as one of the world's leading independent organizations committed to advancing the quality of healthcare.



Related Links:
ECRI

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.